Skip to main content
. 2018 Jul 10;29(2):1032–1038. doi: 10.1007/s00330-018-5618-5

Table 3.

Cox regression model for adjusted hazard ratios for the association of target tumour enhancement at 10-min delayed phase imaging (Target TuEn10) on gadoxetate-enhanced MRI and overall survival (n = 63)

Adjusted hazard ratio (95% confidence interval) p value
Target TuEn10
 Weak Reference p = 0.009**
 Strong 0.24 (0.08-0.70)
Clinical risk score
 < 3 Reference p = 0.055
 ≥ 3 2.61 (0.98-6.98)

**p < 0.01